| 000 -LEADER |
|---|
| fixed length control field |
03760nam a22004335i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150236.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
120227s2012 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781461424000 |
|
978-1-4614-2400-0 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
Boston, MA : |
| -- |
Springer US, |
| -- |
2012. |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Figlin, Robert A. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Renal Cell Carcinoma |
| Medium |
[electronic resource] : |
| Remainder of title |
Translational Biology, Personalized Medicine, and Novel Therapeutic Targets / |
| Statement of responsibility, etc |
edited by Robert A. Figlin, W. Kimryn Rathmell, Brian I. Rini. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XI, 327p. 34 illus., 31 illus. in color. |
| Other physical details |
online resource. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface -- The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies -- Molecular Biology of Clear Cell Renal Carcinoma -- HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment -- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC -- Molecular Characterization of Renal Cell Carcinoma -- Targeting The Vegf Pathway In Renal Cell Carcinoma -- Angiopoetins and Other Non-VEGF Antiangiogenic Targets In Advanced Renal Cell Carcinoma -- Towards Personalized Cancer Medicine -- Epigenetic Targeting and Histone Deacetylase Inhibition in RCC -- C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma -- Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies -- Carbonic Anhydrase IX: Its role as a biomarker, diagnostic, and therapeutic target in Renal Cell Carcinoma -- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials -- Mechanisms of Resistance to VEGF Directed Therapy and Implications for Future Trial Design -- Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma -- Index. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy. Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
|
|---|
| Topical term or geographic name as entry element |
Cancer Research. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacology/Toxicology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rathmell, W. Kimryn. |
| Relator term |
editor. |
|
|---|
| Personal name |
Rini, Brian I. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9781461423997 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-4614-2400-0 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
